DrugPatentWatch Database Preview
Drugs in Development Information for TAK-659
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for TAK-659?
TAK-659 is an investigational drug.
There have been 326 clinical trials for TAK-659.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2016.
The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).
There are three US patents protecting this investigational drug and fifty-three international patents.
Summary for TAK-659
| US Patents | 3 |
| International Patents | 53 |
| US Patent Applications | 10 |
| WIPO Patent Applications | 5 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2016-06-01) |
| Vendors | 10 |
Recent Clinical Trials for TAK-659
| Title | Sponsor | Phase |
|---|---|---|
| Effect of TAK-071 on Falls in Patients With Parkinson Disease | Takeda | Phase 2 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Takeda | Phase 1 |
| A Safety and Efficacy Study of TAK-981 Plus Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | Takeda Development Center Americas, Inc. | Phase 1/Phase 2 |
Clinical Trial Summary for TAK-659
Top disease conditions for TAK-659
Top clinical trial sponsors for TAK-659
US Patents for TAK-659
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TAK-659 | Start Trial | Fused heteroaromatic pyrrolidinones | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| TAK-659 | Start Trial | Fused heteroaromatic pyrrolidinones | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| TAK-659 | Start Trial | Fused heteroaromatic pyrrolidinones as SYK inhibitors | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TAK-659
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TAK-659 | Argentina | 081797 | 2029-12-23 | Start Trial |
| TAK-659 | Australia | 2010333804 | 2029-12-23 | Start Trial |
| TAK-659 | Brazil | 112012015651 | 2029-12-23 | Start Trial |
| TAK-659 | Canada | 2786950 | 2029-12-23 | Start Trial |
| TAK-659 | Chile | 2012001745 | 2029-12-23 | Start Trial |
| TAK-659 | China | 102753548 | 2029-12-23 | Start Trial |
| TAK-659 | Colombia | 6592058 | 2029-12-23 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
